Antifibrotic therapy for the treatment of pulmonary fibrosis.
Fibroproliferative lung disease is prevalent and associated with high mortality. The pathogenesis of fibrotic lung disease involves inflammation, mesenchymal cell proliferation, and deposition of interstitial matrix components, such as collagen and fibronectin. Corticosteroids and other immunosuppressive medications have been routinely employed, but have demonstrated only marginal efficacy. Even though this information has been known for some time, the optimal medical regimen for treating pulmonary fibrosis remains largely undefined. This article addresses the rationale for, and efficacy of, antifibrotic regimens used to treat humans with fibrotic lung diseases.
Lasky
J A
JA
Department of Medicine, Tulane University Medical Center, New Orleans, Louisiana 70112, USA. jlasky@tulane.edu
Ortiz
L A
LA
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003078:Colchicine / Q000627:therapeutic use; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D007371:Interferon-gamma / Q000627:therapeutic use; D009525:Niacin / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000188:drug therapy*; D011728:Pyridones / Q000627:therapeutic use; D011994:Recombinant Proteins; D013654:Taurine / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D007370:Interferon Type I; D011728:Pyridones; D011994:Recombinant Proteins; D013654:Taurine; D009525:Niacin; D007371:Interferon-gamma; C093844:pirfenidone; D010396:Penicillamine; D003078:Colchicine